
Shingrix May Cut Dementia Risk in Older Americans, Large Study Finds
A large U.S. Medicare study (1.5 million beneficiaries) found that older adults who received the two-dose recombinant zoster vaccine (Shingrix) had a lower incidence of dementia than unvaccinated peers, with about a 28–33% reduced risk for any dementia, Alzheimer's disease, and vascular dementia over up to three years and continued protection beyond three years; results are observational and can’t prove causality, but align with other real-world evidence and call for trials to confirm.





